LT3660013T - Tgs stimuliatoriai - Google Patents

Tgs stimuliatoriai

Info

Publication number: LT3660013T
Authority: LT; Lithuania
Prior art keywords: sgc stimulators; sgc; stimulators
Prior art date: 2013-03-15

Application number

LTEP19208775.7T

Other languages

English (en)

Inventor

Takashi Nakai

Joel Moore

Nicholas Robert Perl

Rajesh R. Iyengar

Ara Mermerian

G-Yoon Jamie Im

Thomas Wai-Ho Lee

Colleen Hudson

Glen Robert RENNIE

James Jia

Paul Allen RENHOWE

Timothy Claude Barden

Xiang Y Yu

James Edward SHEPPECK

Karthik Iyer

Joon Jung

George Todd MILNE

Kimberly Kafadar LONG

Mark G. Currie

Original Assignee

Cyclerion Therapeutics, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-15

Filing date

2014-03-14

Publication date

2022-04-11

2014-03-14 Application filed by Cyclerion Therapeutics, Inc. filed Critical Cyclerion Therapeutics, Inc.

2022-04-11 Publication of LT3660013T publication Critical patent/LT3660013T/lt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)
Pyridine Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

LTEP19208775.7T 2013-03-15 2014-03-14 Tgs stimuliatoriai LT3660013T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361790637P	2013-03-15	2013-03-15
US201361914915P	2013-12-11	2013-12-11

Publications (1)

Publication Number	Publication Date
LT3660013T true LT3660013T (lt)	2022-04-11

Family

ID=50513493

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LTEP19208775.7T LT3660013T (lt)	2013-03-15	2014-03-14	Tgs stimuliatoriai
LTEP14718278.6T LT2970243T (lt)	2013-03-15	2014-03-14	Sgc stimuliatoriai

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
LTEP14718278.6T LT2970243T (lt)	2013-03-15	2014-03-14	Sgc stimuliatoriai

Country Status (23)

Country	Link
US (8)	US9481689B2 (lt)
EP (3)	EP2970243B1 (lt)
JP (5)	JP2016517432A (lt)
KR (3)	KR102218771B1 (lt)
CN (5)	CN109384778B (lt)
AU (4)	AU2014227862C1 (lt)
BR (1)	BR112015023349A2 (lt)
CA (1)	CA2907111C (lt)
CY (2)	CY1122919T1 (lt)
DK (2)	DK3660013T3 (lt)
EA (2)	EA031746B1 (lt)
ES (3)	ES2774295T3 (lt)
HR (2)	HRP20220376T1 (lt)
HU (2)	HUE059178T2 (lt)
IL (4)	IL285564B2 (lt)
LT (2)	LT3660013T (lt)
ME (1)	ME03664B (lt)
MX (3)	MX384408B (lt)
PL (2)	PL3660013T3 (lt)
PT (2)	PT3660013T (lt)
RS (2)	RS63108B1 (lt)
SI (2)	SI3660013T1 (lt)
WO (1)	WO2014144100A2 (lt)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2135583B1 (en)	2001-12-20	2012-04-18	TriVascular, Inc.	Advanced endovascular graft
CA3035048C (en)	2010-12-23	2021-05-04	Mark Deem	System for mitral valve repair and replacement
EP4623867A3 (en)	2011-06-21	2025-11-05	Twelve, Inc.	Prosthetic heart valve devices
US9655722B2 (en)	2011-10-19	2017-05-23	Twelve, Inc.	Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
US9763780B2 (en)	2011-10-19	2017-09-19	Twelve, Inc.	Devices, systems and methods for heart valve replacement
WO2013059743A1 (en)	2011-10-19	2013-04-25	Foundry Newco Xii, Inc.	Devices, systems and methods for heart valve replacement
US11202704B2 (en)	2011-10-19	2021-12-21	Twelve, Inc.	Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
US9039757B2 (en)	2011-10-19	2015-05-26	Twelve, Inc.	Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
EP2750631B1 (en)	2011-10-19	2022-11-30	Twelve, Inc.	Prosthetic heart valve devices
EP2797915B1 (en) *	2011-12-27	2016-07-13	Ironwood Pharmaceuticals, Inc.	2-benzyl-3-(oxazole/thiazole)-5-(pyrimidin-2-yl)-1(H)-pyrazole derivatives as stimulators of the soluble guanylate cyclase (sGC) for the treatment of e.g. hypertension or heart failure
US9579198B2 (en)	2012-03-01	2017-02-28	Twelve, Inc.	Hydraulic delivery systems for prosthetic heart valve devices and associated methods
CA2885645A1 (en)	2012-09-19	2014-03-27	Ironwood Pharmaceuticals, Inc.	Sgc stimulators
LT3660013T (lt) *	2013-03-15	2022-04-11	Cyclerion Therapeutics, Inc.	Tgs stimuliatoriai
CA2910948C (en)	2013-05-20	2020-12-29	Twelve, Inc.	Implantable heart valve devices, mitral valve repair devices and associated systems and methods
MX2016007522A (es) *	2013-12-11	2017-12-15	Ironwood Pharmaceuticals Inc	Estimuladores de guanilato ciclasa soluble (sgc).
EP3094327A1 (en)	2014-01-13	2016-11-23	Ironwood Pharmaceuticals, Inc.	USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
WO2016044445A2 (en) *	2014-09-17	2016-03-24	Ironwood Pharmaceuticals, Inc.	sGC STIMULATORS
CN107223125B (zh) *	2014-09-17	2019-09-27	赛科理音医疗有限公司	sGC刺激剂
US20170291889A1 (en)	2014-09-17	2017-10-12	Ironwood Pharmaceuticals, Inc.	Pyrazole derivatives as sgc stimulators
US10844064B2 (en)	2014-09-17	2020-11-24	Cyclerion Therapeutics, Inc.	sGC stimulators
MX2017004543A (es)	2014-10-06	2017-10-04	Vertex Pharma	Moduladores de regulador de conductancia transmembranal de fibrosis quística.
HRP20201932T4 (hr)	2015-07-23	2024-02-16	Bayer Pharma Aktiengesellschaft	Stimulatori / aktivatori topive gvanilat-ciklaze u kombinaciji s nep-inhibitorom i/ili angiotenzin aii-antagonistom i njihova uporaba
EP3337428B1 (en)	2015-08-21	2024-09-25	Twelve Inc.	Mitral valve repair devices
CA3006746C (en) *	2015-11-30	2024-01-30	Ironwood Pharmaceuticals, Inc.	Solid dispersions comprising a sgc stimulator
CA3006764A1 (en) *	2015-12-14	2017-06-22	Ironwood Pharmaceuticals, Inc.	Use of sgc stimulators for the treatment of gastrointestinal sphincter dysfunction
US11420944B2 (en)	2016-01-12	2022-08-23	Nippon Chemiphar Co., Ltd.	Voltage-dependent t-type calcium channel blocker
IL260701B (en) *	2016-02-01	2022-09-01	Ironwood Pharmaceuticals Inc	Use of certain sgc stimulators and salts thereof in the preparation of medicaments for the treatment of nonalcoholic steatohepatitis (nash)
PL3436446T3 (pl)	2016-03-31	2023-09-11	Vertex Pharmaceuticals Incorporated	Modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa
CN105753783B (zh) *	2016-04-08	2017-12-15	李文淏	一种合成塞来昔布的方法
WO2017189276A1 (en)	2016-04-29	2017-11-02	Medtronic Vascular Inc.	Prosthetic heart valve devices with tethered anchors and associated systems and methods
US10889577B2 (en) *	2016-07-07	2021-01-12	Cyclerion Therapeutics, Inc.	Solid forms of an sGC stimulator
CN109563077A (zh) *	2016-07-07	2019-04-02	铁木医药有限公司	用于制备可溶性鸟苷酸环化酶刺激剂的新方法
EP3481821B1 (en)	2016-07-07	2023-09-06	Cyclerion Therapeutics, Inc.	Novel processes for preparation of soluble guanylate cyclase stimulators
KR102513343B1 (ko) *	2016-07-07	2023-03-22	사이클리온 테라퓨틱스, 인크.	sGC 자극제의 인 전구약물
WO2018045276A1 (en)	2016-09-02	2018-03-08	Ironwood Pharmaceuticals, Inc.	Fused bicyclic sgc stimulators
EA038096B1 (ru) *	2016-09-23	2021-07-06	Сайклерион Терапьютикс, Инк.	ПРИМЕНЕНИЕ СТИМУЛЯТОРОВ sGC ДЛЯ ЛЕЧЕНИЯ НЕАЛКОГОЛЬНОГО СТЕАТОГЕПАТИТА (NASH)
PT3519401T (pt)	2016-09-30	2021-12-27	Vertex Pharma	Modulador de regulador de condutância transmembranar de fibrose quística, composições farmacêuticas, métodos de tratamento e processo para fazer o modulador
CA3039735A1 (en)	2016-10-11	2018-04-19	Bayer Pharma Aktiengesellschaft	Combination containing sgc activators and mineralocorticoid receptor antagonists
CN110022871A (zh)	2016-10-11	2019-07-16	拜耳制药股份公司	包含sGC刺激物和盐皮质激素受体拮抗剂的组合产品
IL266372B2 (en) *	2016-11-08	2023-11-01	Cyclerion Therapeutics Inc	Running SGC
WO2018107100A1 (en)	2016-12-09	2018-06-14	Vertex Pharmaceuticals Incorporated	Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US20190381039A1 (en)	2016-12-13	2019-12-19	Cyclerion Therapeutics, Inc.	USE OF sGC STIMULATORS FOR THE TREATMENT OF ESOPHAGEAL MOTILITY DISORDERS
US10702378B2 (en)	2017-04-18	2020-07-07	Twelve, Inc.	Prosthetic heart valve device and associated systems and methods
US10433961B2 (en)	2017-04-18	2019-10-08	Twelve, Inc.	Delivery systems with tethers for prosthetic heart valve devices and associated methods
US10575950B2 (en)	2017-04-18	2020-03-03	Twelve, Inc.	Hydraulic systems for delivering prosthetic heart valve devices and associated methods
US10792151B2 (en)	2017-05-11	2020-10-06	Twelve, Inc.	Delivery systems for delivering prosthetic heart valve devices and associated methods
US10646338B2 (en)	2017-06-02	2020-05-12	Twelve, Inc.	Delivery systems with telescoping capsules for deploying prosthetic heart valve devices and associated methods
US10709591B2 (en)	2017-06-06	2020-07-14	Twelve, Inc.	Crimping device and method for loading stents and prosthetic heart valves
US11253509B2 (en)	2017-06-08	2022-02-22	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
US10786352B2 (en)	2017-07-06	2020-09-29	Twelve, Inc.	Prosthetic heart valve devices and associated systems and methods
US10729541B2 (en)	2017-07-06	2020-08-04	Twelve, Inc.	Prosthetic heart valve devices and associated systems and methods
AU2018304168B2 (en)	2017-07-17	2023-05-04	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
AR112467A1 (es)	2017-08-02	2019-10-30	Vertex Pharma	Procesos para preparar compuestos
US11389449B2 (en)	2017-09-14	2022-07-19	Cyclerion Therapeutics, Inc.	Treatment of metabolic syndrome with an sGC stimulator
IL273831B2 (en)	2017-10-19	2024-10-01	Vertex Pharma	Crystalline forms and compositions of cftr modulators
WO2019081456A1 (en)	2017-10-24	2019-05-02	Bayer Aktiengesellschaft	USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
EP3720849A2 (en)	2017-12-08	2020-10-14	Vertex Pharmaceuticals Incorporated	Processes for making modulators of cystic fibrosis transmembrane conductance regulator
EP3498298A1 (en)	2017-12-15	2019-06-19	Bayer AG	The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi)
EP3727388A1 (en) *	2017-12-19	2020-10-28	Cyclerion Therapeutics, Inc.	Sgc stimulators
WO2019161534A1 (en) *	2018-02-22	2019-08-29	Ironwood Pharmaceuticals, Inc.	Novel processes and intermediates for preparation of soluble guanylate cyclase stimulators
TWI888947B (zh) *	2018-01-10	2025-07-01	美商賽克瑞恩醫療公司	用於製備可溶性鳥苷酸環化酶刺激劑之新穎方法及中間物
CN108129387B (zh) *	2018-01-31	2020-05-22	南京药石科技股份有限公司	一种合成2-氮杂二环[4．1．0]庚烷-1-甲酸盐酸盐的制备方法
TWI810243B (zh)	2018-02-05	2023-08-01	美商維泰克斯製藥公司	用於治療囊腫纖化症之醫藥組合物
WO2019200246A1 (en)	2018-04-13	2019-10-17	Alexander Russell Abela	Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
CA3098475A1 (en)	2018-04-30	2019-11-07	Bayer Aktiengesellschaft	The use of sgc activators and sgc stimulators for the treatment of cognitive impairment
US11508483B2 (en)	2018-05-30	2022-11-22	Adverio Pharma Gmbh	Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group
KR20250141845A (ko)	2018-07-11	2025-09-29	티센토 쎄라퓨틱스 인크.	미토콘드리아 장애의 치료를 위한 sGC 자극제의 용도
TW202438077A (zh)	2018-12-05	2024-10-01	瑞士商優洛凡特科學公司	維貝隆（ｖｉｂｅｇｒｏｎ）於治療患有良性前列腺增生之男性中膀胱過動症症狀之用途
AU2019396622B2 (en) *	2018-12-13	2024-11-07	Nxt Biomedical, Llc	Blood oxygenation treatment methods and devices
CN113330030A (zh)	2019-01-17	2021-08-31	拜耳公司	确定受试者是否适于用可溶性鸟苷酸环化酶(sGC)的激动剂治疗的方法
BR102019016950A2 (pt) *	2019-08-15	2021-02-23	Inst De Pesquisa Ensino Ciencia E Tecnologia Aplicada Inst Galzu	forma de dosagem intrauretral de medicamento; e dispositivo
MX2022005158A (es) *	2019-10-29	2022-06-08	Cyclerion Therapeutics Inc	Tratamiento de nefropatia diabetica con un estimulador de guanilato ciclasa soluble (sgc).
US20230087609A1 (en)	2020-02-21	2023-03-23	Universiteit Maastricht	USE OF A SOLUBLE GUANYLATE CYCLASE (sGC) STIMULATOR OR OF A COMBINATION OF A sGC STIMULATOR AND AN sGC ACTIVATOR FOR CONDITIONS WHEREIN THE HEME GROUP OF sGC IS OXIDIZED OR WHEREIN sGC IS DEFICIENT IN HEME
EP4110396A1 (en)	2020-02-26	2023-01-04	Universiteit Maastricht	Therapeutic combination for the treatment of brain ischemia and said therapeutic combination for use in the treatment of brain ischemia
CN111440315B (zh) *	2020-04-28	2021-07-02	中国科学院长春应用化学研究所	一种自修复热塑性聚脲弹性体及其制备方法
CN112142716B (zh) *	2020-10-29	2021-08-31	山东新时代药业有限公司	一种5元杂芳基取代的吡嗪衍生物及其应用
CN112569179B (zh) *	2020-12-25	2022-12-27	上海交通大学医学院附属第九人民医院	一种可注射水凝胶体系及其制备方法
CN114957087A (zh) *	2022-04-13	2022-08-30	湖南复瑞生物医药技术有限责任公司	一种帕罗韦德中间体制备方法
CN115932092A (zh) *	2022-12-02	2023-04-07	中国科学院昆明植物研究所	玛咖产品中添加有pde-5抑制剂的检测方法与应用
US20240408116A1 (en) *	2023-06-08	2024-12-12	Ilylt, Llc	Compositions for enhancing sexual pleasure with reduced pharmaceutical load of pde5 inhibitor
US12329775B2 (en)	2023-08-15	2025-06-17	Soundbites Public Benefit Corporation	Composition and method for treating hearing loss
CN117582909B (zh) *	2024-01-19	2024-04-02	天津凯莱英医药科技发展有限公司	一种连续生产5-单硝酸异山梨酯的系统和方法

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US3995631A (en)	1971-01-13	1976-12-07	Alza Corporation	Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US4203440A (en)	1978-10-23	1980-05-20	Alza Corporation	Device having variable volume chamber for dispensing useful agent
US4627850A (en)	1983-11-02	1986-12-09	Alza Corporation	Osmotic capsule
EP0192963B1 (de)	1985-02-27	1988-07-20	Werkzeugmaschinenfabrik Oerlikon-Bührle AG	Schwingungsmesseinrichtung für ein Spiralkegelradgetriebe auf einer Zahnradprüfmaschine
IL92966A (en)	1989-01-12	1995-07-31	Pfizer	Dispensing devices powered by hydrogel
US5721365A (en)	1989-09-15	1998-02-24	Us Health	N-substituted piperazine NONOates
US5304121A (en)	1990-12-28	1994-04-19	Boston Scientific Corporation	Drug delivery system making use of a hydrogel polymer coating
US5324280A (en)	1990-04-02	1994-06-28	Alza Corporation	Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5155137A (en)	1990-09-20	1992-10-13	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Complexes of nitric oxide with polyamines
AU668107B2 (en)	1991-09-24	1996-04-26	United States Of America, Represented By The Secretary, Department Of Health And Human Services, The	Oxygen substituted derivatives of nucleophile-nitric oxide adducts as nitric oxide donor prodrugs
WO1993011433A1 (en)	1991-12-05	1993-06-10	Wallac Oy	Luminescent lanthanide chelates
US5814666A (en)	1992-04-13	1998-09-29	The United States As Represented By The Department Of Health And Human Services	Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents
US5691423A (en)	1992-08-24	1997-11-25	The United States Of America As Represented By The Department Of Health And Human Services	Polysaccharide-bound nitric oxide-nucleophile adducts
US5632981A (en)	1992-08-24	1997-05-27	The United States Of America As Represented By The Department Of Health And Human Services	Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same
US5405919A (en)	1992-08-24	1995-04-11	The United States Of America As Represented By The Secretary Of Health And Human Services	Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions and methods of treating biological disorders
US5910316A (en)	1992-08-24	1999-06-08	The United States Of America, As Represented By The Department Of Health And Human Services	Use of nitric oxide-releasing agents to treat impotency
US5994341A (en)	1993-07-19	1999-11-30	Angiogenesis Technologies, Inc.	Anti-angiogenic Compositions and methods for the treatment of arthritis
DE69425331D1 (de)	1993-10-08	2000-08-24	Us Health	Verwendung von stickstoffoxid freisetzenden verbindungen als arzneimittel zur strahlungssensibilisation fur hypoxische zellen
JP2928079B2 (ja)	1994-02-14	1999-07-28	永信薬品工業股▲ふん▼有限公司	１−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途
US5700830A (en)	1994-11-22	1997-12-23	The United States Of America As Represented By The Department Of Health And Human Services	Use of nitric oxide-releasing agents for reducing metastasis risk
US5470862A (en) *	1995-02-03	1995-11-28	Ohmeda Pharmaceutical Products Division Inc.	Substituted pyrazolyl compounds and methods employing such compounds
US6099562A (en)	1996-06-13	2000-08-08	Schneider (Usa) Inc.	Drug coating with topcoat
HUP9802678A3 (en)	1995-06-21	1999-12-28	Shionogi & Co	Bicyclic amino derivatives and pgd2 antagonist containing the same
US5714511A (en)	1995-07-31	1998-02-03	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs
JP4120993B2 (ja)	1996-12-12	2008-07-16	塩野義製薬株式会社	ヘテロ環縮合ベンゼンカルボン酸アミド誘導体およびそれを含有するｐｇｄ２拮抗剤
JP3215441B2 (ja)	1996-12-13	2001-10-09	塩野義製薬株式会社	ベンゾチオフェンカルボン酸アミド誘導体およびそれを含有するｐｇｄ２拮抗剤
DE19744026A1 (de)	1997-10-06	1999-04-08	Hoechst Marion Roussel De Gmbh	Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE19830430A1 (de)	1998-07-08	2000-01-13	Hoechst Marion Roussel De Gmbh	Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
EP1614678B1 (en)	1998-07-08	2014-01-01	Sanofi-Aventis Deutschland GmbH	Sulfur substituted sulfonylaminocarboxylic acid N-heteroarylamides, their preparation, their use and pharmaceutical preparations comprising them
DE19834044A1 (de)	1998-07-29	2000-02-03	Bayer Ag	Neue substituierte Pyrazolderivate
DE19834047A1 (de)	1998-07-29	2000-02-03	Bayer Ag	Substituierte Pyrazolderivate
GB9824310D0 (en)	1998-11-05	1998-12-30	Univ London	Activators of soluble guanylate cyclase
JP2002532406A (ja)	1998-12-17	2002-10-02	アルザ・コーポレーション	複合コーティングによる液体充填ゼラチンカプセルの放出制御システムへの変換
US6342249B1 (en)	1998-12-23	2002-01-29	Alza Corporation	Controlled release liquid active agent formulation dosage forms
DE19942809A1 (de)	1999-09-08	2001-03-15	Bayer Ag	Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943635A1 (de)	1999-09-13	2001-03-15	Bayer Ag	Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
WO2003022814A1 (en)	2001-09-07	2003-03-20	Ono Pharmaceutical Co., Ltd.	Indole derivatives
US20010051624A1 (en)	2000-04-12	2001-12-13	Jones Thomas R.	Method and compositions for the treatment of allergic conditions using PGD2 receptor antagonists
US20030055077A1 (en)	2000-04-12	2003-03-20	Jones Thomas R.	Method and compositions for the treatment of allergic conditions using pgd2 receptor antagonists
US6878522B2 (en)	2000-07-07	2005-04-12	Baiyong Li	Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
AR031176A1 (es) *	2000-11-22	2003-09-10	Bayer Ag	Nuevos derivados de pirazolpiridina sustituidos con piridina
TWI241190B (en)	2001-02-13	2005-10-11	Aventis Pharma Gmbh	4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
TWI243164B (en)	2001-02-13	2005-11-11	Aventis Pharma Gmbh	Acylated indanyl amines and their use as pharmaceuticals
PE20020856A1 (es)	2001-02-13	2002-11-11	Aventis Pharma Gmbh	1,2,3,4-tetrahidronaftil aminas aciladas
MY136316A (en)	2001-02-13	2008-09-30	Sanofi Aventis Deutschland	Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical.
US6511911B1 (en)	2001-04-03	2003-01-28	Advanced Micro Devices, Inc.	Metal gate stack with etch stop layer
EP1424325A4 (en)	2001-09-07	2005-12-21	Ono Pharmaceutical Co	INDOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICAMENTS CONTAINING THEM AS AN ACTIVE AGENT
SE0200411D0 (sv)	2002-02-05	2002-02-05	Astrazeneca Ab	Novel use
SE0200356D0 (sv)	2002-02-05	2002-02-05	Astrazeneca Ab	Novel use
DE10216145A1 (de)	2002-04-12	2003-10-23	Bayer Ag	Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom
DE10220570A1 (de)	2002-05-08	2003-11-20	Bayer Ag	Carbamat-substituierte Pyrazolopyridine
EP1505061A4 (en)	2002-05-16	2007-08-22	Shionogi & Co	CONNECTION WITH PGD-2 RECEPTOR ANTAGONISM
JPWO2003097042A1 (ja)	2002-05-16	2005-09-15	塩野義製薬株式会社	Ｐｇｄ２受容体拮抗剤
TW200307542A (en)	2002-05-30	2003-12-16	Astrazeneca Ab	Novel compounds
SE0201635D0 (sv)	2002-05-30	2002-05-30	Astrazeneca Ab	Novel compounds
SE0202241D0 (sv)	2002-07-17	2002-07-17	Astrazeneca Ab	Novel Compounds
DE10244810A1 (de) *	2002-09-26	2004-04-08	Bayer Ag	Neue Morpholin-überbrückte Indazolderivate
US7211672B2 (en)	2002-10-04	2007-05-01	Millennium Pharmaceuticals, Inc.	PGD2 receptor antagonists for the treatment of inflammatory diseases
EA011087B1 (ru)	2002-12-20	2008-12-30	Эмджен Инк.	Соединения и фармацевтические композиции для лечения воспалительных заболеваний
CN100439371C (zh) *	2003-04-29	2008-12-03	辉瑞大药厂	可用于治疗高血压的5,7-二氨基吡唑并[4,3-d]嘧啶
EP1479679A1 (en)	2003-05-19	2004-11-24	Aventis Pharma Deutschland GmbH	Triazole-derivatives as factor Xa inhibitors
CA2534371A1 (en)	2003-08-04	2005-02-10	Pfizer Products Inc.	Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
US8309608B2 (en)	2003-11-06	2012-11-13	Sanofi-Aventis Deutschland Gmbh	Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases
US20100144864A1 (en)	2007-04-05	2010-06-10	Ironwood Pharmaceuticals, Inc.	Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
WO2009032249A1 (en) *	2007-09-06	2009-03-12	Merck & Co., Inc.	Soluble guanylate cyclase activators
JP2011510082A (ja)	2008-01-24	2011-03-31	メルク・シャープ・エンド・ドーム・コーポレイション	アンジオテンシンｉｉ受容体拮抗薬
MX2010012228A (es) *	2008-05-10	2010-12-07	Bayer Schering Pharma Ag	Estimuladores de sgc, activadores de sgc y combinaciones de los mismos para el tratamiento de la deficiencia auditiva.
US8741910B2 (en)	2008-11-25	2014-06-03	Merck Sharp & Dohme Corp.	Soluble guanylate cyclase activators
MX2011008952A (es)	2009-02-26	2011-09-27	Merck Sharp & Dohme	Activadores de guanilato ciclasa solubles.
US20130178475A1 (en)	2010-03-17	2013-07-11	Ironwood Pharmaceuticals, Inc.	sGC STIMULATORS
WO2011119518A1 (en)	2010-03-25	2011-09-29	Merck Sharp & Dohme Corp.	Soluble guanylate cyclase activators
WO2011135894A1 (ja)	2010-04-27	2011-11-03	日本電気株式会社	情報処理端末およびその制御方法
MX2012013774A (es)	2010-05-27	2012-12-17	Merck Sharp & Dohme	Activadores de guanilato ciclasa soluble.
DK2588465T3 (en) *	2010-06-30	2017-05-01	Ironwood Pharmaceuticals Inc	SGC stimulators
WO2012058132A1 (en)	2010-10-28	2012-05-03	Merck Sharp & Dohme Corp.	Soluble guanylate cyclase activators
RU2582679C2 (ru)	2010-11-09	2016-04-27	Айронвуд Фармасьютикалз, Инк.	СТИМУЛЯТОРЫ sGC
US9284298B2 (en) *	2011-04-11	2016-03-15	Nerviano Medical Sciences S.R.L.	Pyrazolyl-pyrimidine derivatives as kinase inhibitors
CA2859779A1 (en)	2011-12-21	2013-06-27	Bayer Intellectual Property Gmbh	Substituted benzylpyrazoles
EP2797915B1 (en)	2011-12-27	2016-07-13	Ironwood Pharmaceuticals, Inc.	2-benzyl-3-(oxazole/thiazole)-5-(pyrimidin-2-yl)-1(H)-pyrazole derivatives as stimulators of the soluble guanylate cyclase (sGC) for the treatment of e.g. hypertension or heart failure
DE102012200352A1 (de)	2012-01-11	2013-07-11	Bayer Intellectual Property Gmbh	Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung
US9309235B2 (en)	2012-09-18	2016-04-12	Ironwood Pharmaceuticals, Inc.	SGC stimulators
CA2885645A1 (en)	2012-09-19	2014-03-27	Ironwood Pharmaceuticals, Inc.	Sgc stimulators
LT3660013T (lt)	2013-03-15	2022-04-11	Cyclerion Therapeutics, Inc.	Tgs stimuliatoriai
MX2016007522A (es)	2013-12-11	2017-12-15	Ironwood Pharmaceuticals Inc	Estimuladores de guanilato ciclasa soluble (sgc).
EP3094327A1 (en)	2014-01-13	2016-11-23	Ironwood Pharmaceuticals, Inc.	USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS

2014
- 2014-03-14 LT LTEP19208775.7T patent/LT3660013T/lt unknown
- 2014-03-14 KR KR1020157029189A patent/KR102218771B1/ko active Active
- 2014-03-14 MX MX2018014773A patent/MX384408B/es unknown
- 2014-03-14 PT PT192087757T patent/PT3660013T/pt unknown
- 2014-03-14 SI SI201431948T patent/SI3660013T1/sl unknown
- 2014-03-14 ES ES14718278T patent/ES2774295T3/es active Active
- 2014-03-14 KR KR1020227004444A patent/KR102502937B1/ko active Active
- 2014-03-14 EP EP14718278.6A patent/EP2970243B1/en active Active
- 2014-03-14 ME MEP-2020-40A patent/ME03664B/me unknown
- 2014-03-14 KR KR1020217004630A patent/KR102362835B1/ko active Active
- 2014-03-14 DK DK19208775.7T patent/DK3660013T3/da active
- 2014-03-14 JP JP2016502769A patent/JP2016517432A/ja active Pending
- 2014-03-14 CN CN201811216402.XA patent/CN109384778B/zh active Active
- 2014-03-14 RS RS20220352A patent/RS63108B1/sr unknown
- 2014-03-14 HR HRP20220376TT patent/HRP20220376T1/hr unknown
- 2014-03-14 PL PL19208775T patent/PL3660013T3/pl unknown
- 2014-03-14 HU HUE19208775A patent/HUE059178T2/hu unknown
- 2014-03-14 EP EP21214096.6A patent/EP3998260B1/en active Active
- 2014-03-14 EP EP19208775.7A patent/EP3660013B1/en active Active
- 2014-03-14 ES ES19208775T patent/ES2911276T3/es active Active
- 2014-03-14 CA CA2907111A patent/CA2907111C/en active Active
- 2014-03-14 CN CN201480027900.3A patent/CN105408328B/zh active Active
- 2014-03-14 DK DK14718278.6T patent/DK2970243T3/da active
- 2014-03-14 EA EA201591743A patent/EA031746B1/ru unknown
- 2014-03-14 MX MX2015012473A patent/MX361208B/es active IP Right Grant
- 2014-03-14 CN CN201810569286.3A patent/CN108912111B/zh active Active
- 2014-03-14 LT LTEP14718278.6T patent/LT2970243T/lt unknown
- 2014-03-14 AU AU2014227862A patent/AU2014227862C1/en active Active
- 2014-03-14 BR BR112015023349A patent/BR112015023349A2/pt not_active Application Discontinuation
- 2014-03-14 US US14/775,954 patent/US9481689B2/en active Active
- 2014-03-14 CN CN201811217841.2A patent/CN110016020B/zh active Active
- 2014-03-14 WO PCT/US2014/028370 patent/WO2014144100A2/en not_active Ceased
- 2014-03-14 CN CN201811217263.2A patent/CN109369635B/zh active Active
- 2014-03-14 SI SI201431503T patent/SI2970243T1/sl unknown
- 2014-03-14 IL IL285564A patent/IL285564B2/en unknown
- 2014-03-14 HR HRP20200276TT patent/HRP20200276T1/hr unknown
- 2014-03-14 PT PT147182786T patent/PT2970243T/pt unknown
- 2014-03-14 RS RS20200218A patent/RS59981B1/sr unknown
- 2014-03-14 HU HUE14718278A patent/HUE048543T2/hu unknown
- 2014-03-14 ES ES21214096T patent/ES2966517T3/es active Active
- 2014-03-14 PL PL14718278T patent/PL2970243T3/pl unknown
- 2014-03-14 EA EA201890641A patent/EA033168B1/ru unknown
2015
- 2015-09-11 MX MX2021008281A patent/MX2021008281A/es unknown
- 2015-09-16 IL IL24164115A patent/IL241641B/en active IP Right Grant
2016
- 2016-07-21 US US15/215,628 patent/US9586937B2/en active Active
- 2016-08-24 US US15/245,697 patent/US10183021B2/en active Active
2017
- 2017-01-16 US US15/406,994 patent/US20170137439A1/en not_active Abandoned
- 2017-01-16 US US15/406,959 patent/US10517874B2/en active Active
- 2017-04-14 JP JP2017080301A patent/JP6267385B2/ja active Active
- 2017-04-14 JP JP2017080300A patent/JP6267384B2/ja active Active
2018
- 2018-10-12 JP JP2018193191A patent/JP6709000B2/ja active Active
- 2018-11-02 US US16/178,771 patent/US10639308B2/en active Active
2019
- 2019-05-22 AU AU2019203606A patent/AU2019203606B9/en active Active
- 2019-11-14 IL IL270646A patent/IL270646B/en active IP Right Grant
2020
- 2020-02-27 CY CY20201100188T patent/CY1122919T1/el unknown
- 2020-03-13 US US16/817,830 patent/US11207323B2/en active Active
- 2020-05-07 JP JP2020081703A patent/JP7072602B2/ja active Active
- 2020-12-23 IL IL279695A patent/IL279695B/en unknown
2021
- 2021-06-24 AU AU2021204292A patent/AU2021204292B2/en active Active
- 2021-12-20 US US17/556,213 patent/US20230106002A1/en active Pending
2022
- 2022-04-13 CY CY20221100280T patent/CY1125178T1/el unknown
2023
- 2023-04-04 AU AU2023202058A patent/AU2023202058B2/en active Active

Also Published As

Publication number	Publication date
CN105408328B (zh)	2018-11-16
AU2023202058B2 (en)	2025-03-20
DK3660013T3 (da)	2022-03-28
CN110016020A (zh)	2019-07-16
ME03664B (me)	2020-10-20
AU2019203606B2 (en)	2021-03-25
US20170136019A1 (en)	2017-05-18
US11207323B2 (en)	2021-12-28
EA201591743A8 (ru)	2017-12-29
IL285564A (en)	2021-09-30
ES2966517T3 (es)	2024-04-22
KR20150129002A (ko)	2015-11-18
US20230106002A1 (en)	2023-04-06
SI2970243T1 (sl)	2020-04-30
US20160347738A1 (en)	2016-12-01
US10639308B2 (en)	2020-05-05
EP2970243A2 (en)	2016-01-20
IL241641B (en)	2019-11-28
EP3660013A1 (en)	2020-06-03
US20160031903A1 (en)	2016-02-04
IL279695B (en)	2021-08-31
ES2911276T3 (es)	2022-05-18
CY1122919T1 (el)	2021-10-29
CN110016020B (zh)	2022-07-26
AU2021204292B2 (en)	2023-01-05
MX361208B (es)	2018-11-30
PL2970243T3 (pl)	2020-06-01
EP2970243B1 (en)	2019-11-27
JP6267384B2 (ja)	2018-01-24
MX2021008281A (es)	2022-06-14
PT3660013T (pt)	2022-04-12
JP2017160225A (ja)	2017-09-14
RS59981B1 (sr)	2020-03-31
ES2774295T3 (es)	2020-07-20
US10517874B2 (en)	2019-12-31
PL3660013T3 (pl)	2022-05-02
AU2023202058A1 (en)	2023-05-04
CA2907111C (en)	2023-10-24
CN108912111B (zh)	2021-09-14
IL279695A (en)	2021-01-31
EA031746B1 (ru)	2019-02-28
AU2014227862B2 (en)	2019-02-28
EP3998260B1 (en)	2023-11-01
EP3660013B1 (en)	2022-01-19
US20200316065A1 (en)	2020-10-08
AU2019203606B9 (en)	2021-04-01
AU2023202058A2 (en)	2023-05-25
HUE048543T2 (hu)	2020-07-28
HK1221723A1 (zh)	2017-06-09
SI3660013T1 (sl)	2022-05-31
US20170137439A1 (en)	2017-05-18
DK2970243T3 (da)	2020-03-02
HRP20220376T1 (hr)	2022-07-22
AU2014227862C1 (en)	2019-05-30
JP2016517432A (ja)	2016-06-16
JP7072602B2 (ja)	2022-05-20
HK1213541A1 (en)	2016-07-08
IL285564B2 (en)	2024-06-01
IL270646B (en)	2021-01-31
JP2017178946A (ja)	2017-10-05
JP2019034952A (ja)	2019-03-07
WO2014144100A3 (en)	2014-11-06
US9481689B2 (en)	2016-11-01
CN109369635B (zh)	2023-06-30
RS63108B1 (sr)	2022-04-29
HUE059178T2 (hu)	2022-10-28
KR20220025191A (ko)	2022-03-03
JP6267385B2 (ja)	2018-01-24
AU2021204292A1 (en)	2021-07-22
EP3998260A1 (en)	2022-05-18
HRP20200276T1 (hr)	2020-05-29
IL285564B1 (en)	2024-02-01
EA033168B1 (ru)	2019-09-30
KR102502937B1 (ko)	2023-02-23
CN108912111A (zh)	2018-11-30
AU2019203606A1 (en)	2019-06-13
US9586937B2 (en)	2017-03-07
MX2015012473A (es)	2016-04-19
EA201890641A2 (ru)	2018-07-31
KR20210020181A (ko)	2021-02-23
JP6709000B2 (ja)	2020-06-10
KR102362835B1 (ko)	2022-02-14
US10183021B2 (en)	2019-01-22
PT2970243T (pt)	2020-03-05
EA201591743A1 (ru)	2016-02-29
US20160375022A1 (en)	2016-12-29
KR102218771B1 (ko)	2021-02-19
BR112015023349A2 (pt)	2017-07-18
LT2970243T (lt)	2020-03-10
CN109384778B (zh)	2022-12-13
CY1125178T1 (el)	2024-12-13
MX384408B (es)	2025-03-14
EA201890641A3 (ru)	2018-11-30
JP2020143092A (ja)	2020-09-10
CN109384778A (zh)	2019-02-26
CA2907111A1 (en)	2014-09-18
WO2014144100A2 (en)	2014-09-18
AU2014227862A1 (en)	2015-11-12
CN109369635A (zh)	2019-02-22
CN105408328A (zh)	2016-03-16
EP3998260C0 (en)	2023-11-01
US20190167679A1 (en)	2019-06-06

Publication	Publication Date	Title
IL285564A (en)	2021-09-30	sgc fans
EP2953521A4 (en)	2016-09-21	MANIPULATOR
EP3067168A4 (en)	2016-11-02	MANIPULATOR
HUE036860T2 (hu)	2018-08-28	Adagoló
IL240348A0 (en)	2015-09-24	Transmuted imidazopyridines
EP2977150A4 (en)	2016-11-09	MANIPULATOR
GB2519654B (en)	2015-11-11	Feeder
ZA201600275B (en)	2019-04-24	Substituted pyrazolo-pyridinamines
EP2953770A4 (en)	2016-10-26	MANIPULATOR
IL246271A0 (en)	2016-08-02	Converted piperidinyl-tetrahydroquinolines
GB201417087D0 (en)	2014-11-12	No detials
DK3049043T3 (en)	2021-10-04	Indirekte tryk- og temperaturmåling i et totalt væskeventilationssystem
PL2826522T3 (pl)	2018-12-31	Rozrusznik serca
GB201311130D0 (en)	2013-08-07	Greensleeves I
IL245452B (en)	2020-09-30	Salts of Armachol
GB201304806D0 (en)	2013-05-01	Robot
GB201321164D0 (en)	2014-01-15	Glowfaster gizmo
GB201311131D0 (en)	2013-08-07	Greensleeves II
GB201317353D0 (en)	2013-11-13	Ed